HCA · NYQ · Healthcare
HCA Healthcare, Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 529.15
Market price
USD 427.71
Implied upside
+23.7%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 81.5bn | USD 88.0bn | USD 94.9bn | USD 102.4bn | USD 110.4bn | +7.9% |
| EBIT | USD 12.4bn | USD 13.3bn | USD 14.4bn | USD 15.5bn | USD 16.7bn | +7.9% |
| NOPAT | USD 9.8bn | USD 10.5bn | USD 11.4bn | USD 12.3bn | USD 13.2bn | +7.9% |
| Add depreciation & amortisation | USD 3.9bn | USD 4.2bn | USD 4.5bn | USD 4.9bn | USD 5.2bn | +7.9% |
| Less capital expenditure | USD -5.7bn | USD -6.2bn | USD -6.7bn | USD -7.2bn | USD -7.7bn | +7.9% |
| Less increase in working capital | USD -111.9m | USD -120.7m | USD -130.2m | USD -140.5m | USD -151.5m | +7.9% |
| Free cashflow to firm | USD 7.8bn | USD 8.4bn | USD 9.1bn | USD 9.8bn | USD 10.6bn | +7.9% |
| Discount factor | 0.9600 | 0.8848 | 0.8154 | 0.7515 | 0.6926 | - |
| Present value | USD 7.5bn | USD 7.5bn | USD 7.4bn | USD 7.4bn | USD 7.3bn | -0.6% |
| Present Value Of The Forecast | USD 37.1bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.073 | Reported 1.109, pulled toward 1.0 (Blume) |
| Cost of equity | 10.90% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 92.6bn | 65.5% of capital |
| Total debt | USD 48.7bn | 34.5% of capital, book value as a proxy |
| Tax rate | 20.9% | Effective, capped at statutory |
| WACC | 8.51% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
79% of EV
- Forecast FCFF, final year
- USD 10.6bn
- Capex at depreciation, working capital in reinvestment
- USD 13.2bn
- Less reinvestment at g/ROIC (12.2% of NOPAT)
- USD -1.6bn
- Capitalised
- USD 11.6bn
- ROIC (reported)
- 20.4%
- Terminal value, undiscounted
- USD 198.2bn
- Terminal value, discounted
- USD 137.3bn
- Enterprise value
- USD 174.4bn
- Less net debt
- USD 47.7bn
- Equity value
- USD 126.7bn
Exit at 9.1x EBITDA
79% of EV
- Terminal value, undiscounted
- USD 199.0bn
- Terminal value, discounted
- USD 137.9bn
- Enterprise value
- USD 175.0bn
- Less net debt
- USD 47.7bn
- Equity value
- USD 127.3bn
Spread between methods: 0%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.51% | 745.12 | 813.10 | 897.79 | 1006.36 | 1150.70 |
| 7.51% | 584.34 | 626.34 | 676.55 | 737.67 | 813.82 |
| 8.51% | 469.68 | 497.20 | 529.15 | 566.73 | 611.64 |
| 9.51% | 383.84 | 402.63 | 423.97 | 448.46 | 476.87 |
| 10.51% | 317.22 | 330.43 | 345.19 | 361.80 | 380.65 |
Outlined: this model. Green text: above today's price of 427.71. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 7.9% | 4.3% | -3.5pp |
| EBIT margin | 15.2% | 13.1% | -2.0pp |
| Discount rate | 8.5% | 9.5% | +1.0pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.